首页> 外文期刊>Age and Ageing >Oxybutynin with Bladder Retraining for Detrusor Instability in Elderly People: A Randomized Controlled Trial
【24h】

Oxybutynin with Bladder Retraining for Detrusor Instability in Elderly People: A Randomized Controlled Trial

机译:奥昔布宁联合膀胱复律治疗老年逼尿肌不稳定:一项随机对照试验。

获取原文
获取原文并翻译 | 示例
       

摘要

The aim of this study was to examine the efficacy of oxybutynin plus bladder training in the treatment of detrusor instability in frail elderly patients living independently in the community. It was a randomized, double-blind, placebo-controlled parallel-group trial of oxybutynin in 57 elderly patients (mean age 82.2, SD 6.06), with frequency and incontinence due to detrusor instability. After a 2-week run-in period patients received a bladder training and drug or placebo for the next 6 weeks. Outcome measures were changes in frequency and incontinence, recorded throughout on diary charts, and subjective evaluation of symptoms ('better'/'not better', and using a four-point scale 'cure' to 'no change'). Oxybutynin was superior to placebo in reducing daytime frequency [95% confidence interval (CI) of difference in change in frequencies totalled over 14 days was -27.0, -6.0; p = 0.003] and in producing subjective benefit (at day 29 only), when 24/28 (86%) patients on oxybutynin described benefit compared with 16/29 (55%) on placebo (p = 0.02). There was no difference between the groups in reduction of incontinent episodes. The median dose of oxybutynin titrated for therapeutic effect was 5 mg/day, and for placebo 10 mg/day (CI of difference 0.001, 5.001; p = 0.05). Side-effects reported were of similar frequency (50%) in the two groups. We conclude that oxybutynin with bladder training is superior to bladder training alone in reducing frequency due to detrusor instability in very elderly people living at home.
机译:这项研究的目的是检查奥昔布宁加膀胱训练在社区独立生活的衰弱老年患者中逼尿肌不稳定的疗效。这是一项针对57例老年患者(平均年龄82.2,SD 6.06)的奥昔布宁随机,双盲,安慰剂对照平行组试验,其因逼尿肌不稳定而发生频率和失禁。经过2周的磨合期后,患者在接下来的6周接受了膀胱训练以及药物或安慰剂。结果指标是频率和大小便失禁的变化,记录在日记本图表上,对症状进行主观评估(“更好” /“不太好”,并使用四点量表“治愈”为“无变化”)。奥昔布宁在降低白天频率方面优于安慰剂[14天总频率变化的差异的95%置信区间(CI)为-27.0,-6.0; p = 0.003],并且在产生主观益处时(仅在第29天),使用奥昔布宁的患者中有24/28(86%)患者描述了获益,而使用安慰剂的患者则为16/29(55%)(p = 0.02)。两组之间尿失禁发作的减少没有差异。为治疗效果滴定的奥昔布宁的中位剂量为5 mg /天,安慰剂为10 mg /天(CI差异0.001,5.001; p = 0.05)。两组中报道的副作用发生频率相似(50%)。我们得出结论,奥昔布宁联合膀胱训练优于单独的膀胱训练,在减少因居家中老年人逼尿肌不稳定引起的频率方面。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号